At a glance
ClinicalIndex Comparison RecordN/ACompleted· 387 enrolled
Drug / intervention
bimatoprost 0.01% ophthalmic solutiondrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Observational Study of Lumigan® 0.01% Treatment for Patients With Primary Open Angle Glaucoma or Ocular Hypertension
In Brief
An observational study evaluating bimatoprost 0.01% ophthalmic solution for Glaucoma, Open-Angle and Ocular Hypertension. Completed, enrolled 387 participants across 1 site.
Detailed Summary
This study will assess the efficacy, safety, tolerability and persistence of use of Lumigan ® 0.01% in patients diagnosed with primary open-angle glaucoma or ocular hypertension who are treated per routine clinical practice.
Study Details
Study Typeobservational
Allocation--
Masking--
Primary Purpose--
ConditionsGlaucoma, Open-Angle, Ocular Hypertension
CountriesSwitzerland
Collaborators--
Timeline
N/ACompletedFinished
201220132014201520162017201820192020202120222023202420252026
Enrollment StartSep 2011
First PostedDec 2011
Primary CompletionMar 2013
TodayJul 2026
First PostedDec 12, 2011
Enrollment StartSep 1, 2011
Primary CompletionMar 1, 2013
TodayJul 2, 2026
Enrollment to primary: 1.5 yearsPosted 14.6 years ago
Interventions
bimatoprost 0.01% ophthalmic solutiondrug
Patients with primary open-angle glaucoma or ocular hypertension treated with Lumigan® 0.01% in clinical practice.